Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01177527 · ClinicalTrials.gov registry record
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
A clinical trial of Multiple Myeloma and Lymphoblastic Lymphoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 656
- Enrollment target
- 1
- Study location
NCT01177527: Active study of Multiple Myeloma and Lymphoblastic Lymphoma, sponsored by Dana-Farber Cancer Institute.
NCT01177527 is a study of Multiple Myeloma and Lymphoblastic Lymphoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 656 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01177527, a study of Multiple Myeloma and Lymphoblastic Lymphoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 656 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS and IgG or IgA LPL. These samples will become part of a tissue bank and will be used in ongoing studies to find out more about the causes and biology of MM, WM and LPL; to identify what factors result in normal cells becoming cancer; to determine how to improve treatment options; to study how the immune system identifies abnormal cells; and to evaluate the immune function in these diseases. The investigators will also study the tumor cells at the level of the participant's genes to develop treatment strategies as well as to better understand how biologic differences affect patient outcomes.
Primary Outcome
To establish a databank of patients with MM, WM, MGUS, sMM, or related disorders. This databank will include medical history data and bone marrow and peripheral blood samples.
Conditions Studied
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 656 participants |
| Start Date | 2009-12 |
| Est. Completion | 2026-01 |
What the registry record for NCT01177527 still lists
NCT01177527 is an observational study that tracks outcomes without assigning an intervention. The registered 656 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (20% higher).
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT01177527 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01177527 about?
NCT01177527 is a clinical study titled "Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders". The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic lymphomas (LPL) including but not limited to MGUS and IgG or IgA LPL. T...
What is the current status of trial NCT01177527?
This trial is currently active not recruiting. The enrollment target is 656 participants. The study started on 2009-12. Estimated completion is 2026-01.
What conditions does trial NCT01177527 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoblastic Lymphoma, Smoldering Multiple Myeloma, Waldenstrom's Macroglobulinemia.
Who is sponsoring clinical trial NCT01177527?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01177527 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01177527's enrollment target sits among peer trials
656 35th of 438 higher than 404 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05407129 · 656 participants · NA
Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences
- NCT06127199 · 656 participants · NA
Contraceptive Efficacy Study of Ovaprene
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia